PAVmed exchanges $22.35M of convertible notes for Series C preferred; targets Nasdaq compliance

PAVmed Inc.

Exchanged $22,347,543 in principal plus interest of Senior Secured Convertible Notes for 22,347 Series C Preferred shares.
Remaining outstanding principal on Convertible Notes is approximately $6.6 million.
Potential dilution: at voluntary conversion price $1.068/share, ~20.9M common shares; at floor $0.2136, ~104.6M shares.
Company executed exchange to bolster stockholders' equity to meet Nasdaq minimum of $2.5M; compliance deadline Jan 31, 2025.

item 3.01 item 3.02 item 3.03 item 5.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.4

PAVmed Inc.: Information incorporated by reference from Item 3.02; no substantive change described.

Exact text from the filing

The information set forth and incorporated by reference under Item 3.02 is incorporated under this item by reference.

View on SEC.gov

Browse all governance changes →

PAVmed Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-003053

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.